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The epidermal phenotype as observed in psoriatic skin results from inﬂammation and abnormal proliferation and
terminal differentiation of keratinocytes. Mice deﬁcient for interferon regulatory factor-2, a repressor of interferon
signaling, display psoriasis-like skin inﬂammation. The development of this phenotype is strictly dependent on
type I interferon (interferon-a/b) signaling. The aim of this study was to assess the involvement of interferon-a/b in
the pathogenesis of human psoriasis. In psoriatic skin, we measured an increased expression of components that
play central and crucial roles in interferon-a/b signal transduction. Culturing keratinocytes or healthy skin biopsies
with recombinant interferon-a stimulated this signaling pathway; however, this did not induce the expression of
markers that are generally used to deﬁne the psoriasis phenotype. Furthermore, skin from psoriasis patients
responded identically to interferon-a stimulation, demonstrating that psoriatic skin does not have an aberrant
sensitivity to type I interferon. We conclude that in psoriatic lesional skin the type I interferon signaling pathway is
activated, despite an unaltered interferon-a sensitivity. Our data furthermore show that type I interferon, in contrast
to interferon-c, does not act directly on keratinocytes to induce a psoriatic phenotype. Thus, if the observed
activated type I interferon signaling is indeed functionally involved in the pathogenesis of psoriasis, its
contribution might be indirect, putatively involving other cell types besides keratinocytes.
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Interferons (IFN) are cytokines that play a central and
complex role in defending the mammalian host to patho-
gens. Type I IFN (IFN-a/b) are secreted by virus-infected
cells, and are required to mount an effective anti-viral
response. Type II IFN (IFN-g) is produced by activated T
cells and natural killer cells, and is implicated mainly in
regulating adaptive immune responses. The link between
type I IFN and autoimmunity is apparent in the literature,
although evidence supporting this is merely circumstantial.
Associations have been reported between viral infections
and autoimmune disorders, such as autoimmune thyroid
disease, rheumatoid arthritis, and systemic lupus erythe-
matosus (McMurray and Elbourne, 1997). Furthermore,
case reports showed that patients treated with IFN-a can
develop autoimmune diseases (Unoki et al, 1996; Pittau
et al, 1997; Fukuyama et al, 2000; Recasens et al, 2001).
Although the chronic inflammatory skin disease psoriasis
does not meet all criteria for autoimmune diseases (Rose
and Bona, 1993), it shares many characteristics with
autoimmune disorders (Davidson and Diamond, 2001).
Therefore, in analogy to the above-mentioned autoimmune
diseases, a role for type I IFN in the pathogenesis of
psoriasis is plausible. Associations between chronic viral
infections and the development of psoriasis have been
reported (e.g., Yamamoto et al, 1995; Erkek et al, 2000).
Furthermore, it has been observed that psoriasis can be
induced or exacerbated by IFN-a treatment (e.g., Pauluzzi
et al, 1993; Erkek et al, 2000). More direct evidence for the
involvement of type I IFN in the pathogenesis of psoriasis
comes from studies on mice deficient for interferon
regulatory factor (IRF)-2, a transcriptional repressor of IFN
signaling. These mice display psoriasis-like skin abnormal-
ities, characterized by increased epidermal intercellular
adhesion molecule (ICAM)-1 expression and infiltrates of
CD4þ and CD8þ T cells. IFN-a/b signaling appeared to be
absolutely required for the development of this skin
phenotype, as mice deficient for both IRF-2 and the type I
IFN receptor displayed no signs of skin inflammation (Hida
et al, 2000).
To elucidate the role for type I IFN in the pathogenesis of
psoriasis in humans, we studied the expression of type I IFN
signaling components in healthy and psoriatic skin. Activa-
tion of the type I IFN receptor results in the formation of the
heterotrimeric transcription factor complex interferon sti-
mulated gene factor (ISGF)3, which is composed of
phosphorylated signal transducer and activator of tran-
scription (STAT)1, STAT2, and IRF-9. Upon translocation into
the nucleus, this complex is capable of activating IFN-
inducible genes (Taniguchi et al, 2001). IRF-7 is one of the
Abbreviations: ICAM, intercellular adhesion molecule; IRF,
interferon regulatory factor; ISGF, interferon stimulated gene
factor; K17, keratin 17; RT-PCR, reverse transcription-
polymearse chain reaction; STAT, signal transducer and
activator of transcription.
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genes that is transcriptionally induced by, and completely
dependent on, the formation and nuclear translocation of
ISGF3 (Sato et al, 1998). IRF-7 itself also acts as a
transcription factor and shares homology with other IRF
family members in its DNA-binding domain (Taniguchi et al,
2001).
We demonstrate that the expression of components that
are involved in type I IFN signal transduction is markedly
increased in psoriatic skin, implying functional activation of
this signaling pathway. In vitro activation of this pathway in
cultured keratinocytes or skin biopsies did not induce the
expression of markers that are characteristic for the
psoriatic skin phenotype. Furthermore, nonlesional and
lesional skin biopsies from psoriatic patients responded
identically to IFN-a stimulation as healthy skin biopsies,
demonstrating that psoriatic skin displays a normal sensi-
tivity to type I IFN.
Results
Nuclear expression of STAT1 and IRF-9 is increased in
the psoriatic epidermis The activity of the type I IFN signal
transduction pathway in psoriatic skin was assayed by
determining the expression patterns of several components
of this signaling pathway by immunohistochemistry. STAT1
occupies a central position in both type I and type II IFN
signaling. After activation of the IFN-g receptor, homodi-
mers of phosphorylated STAT1 are formed, which are
subsequently translocated into the nucleus. On the other
hand, upon stimulation with IFN-a/b, activated STAT1 forms
a heterotrimeric complex with STAT2 and IRF-9. This ISGF3
complex becomes biologically active when translocated
into the nucleus, and is capable of activating the transcrip-
tion of many genes, among others IRF-7.
Immunohistochemical analysis of healthy skin biopsies
using STAT1 antibodies showed a diffuse cytoplasmic
staining (Fig 1, upper left panel), whereas no epidermal
cells stained positive using a control antibody (normal rabbit
IgG) (data not shown). We observed that in healthy skin,
STAT1 was localized in the nucleus of 36  3% of the
epidermal keratinocytes (Table II). In psoriasis lesional skin,
however, the number of STAT1-positive nuclei was sig-
nificantly increased to 56  5%, implying functional activa-
tion of IFN signaling.
As IRF-9 only forms part of the ISGF3 complex, and is
therefore more restricted to type I IFN signaling, immuno-
histochemical analysis of IRF-9 expression was performed
(Fig 1, middle row). Quantification of the percentages of
epidermal keratinocytes with nuclear IRF-9 expression
revealed that in both nonlesional and lesional skin from
psoriasis patients, the nuclear IRF-9 expression was
Figure 1
STAT1, IRF-9, and IRF-7 proteins are ex-
pressed in the nuclei of keratinocytes. Im-
munohistochemical analysis of STAT1 (upper
panel), IRF-9 (middle panel), and IRF-7 (lower
panel) proteins in healthy (NN, left row), nonle-
sional (PN, middle row), and lesional psoriatic
(PP, right row) skin biopsies. Scale bar¼ 100 mm.
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significantly increased (Table II). IRF-7 protein expression
was detectable in the nucleus of most epidermal cells (Fig 1,
lower row), and the percentages of positive nuclei in healthy,
nonlesional, and lesional psoriatic epidermis were compar-
able (Table II).
IRF-7 mRNA expression is elevated in epidermal cells
from psoriasis skin lesions In addition to the analysis of
IFN signaling components by immunohistochemistry, IRF-9
and IRF-7 mRNA expression was quantified. In total RNA
extracted from epidermal cells, IRF-9 mRNA was detect-
able by quantitative RT–PCR, and the expression levels in
healthy skin, nonlesional and lesional psoriatic skin were
comparable (Fig 2). Quantitative analysis of IRF-7 mRNA
levels, however, revealed that IRF-7 mRNA expression was
significantly increased in psoriatic lesional skin, when
compared with healthy and nonlesional skin. On average,
a 6.2-fold increase was observed (Fig 2).
Thus the increased nuclear localization of both STAT1 and
IRF-9, in combination with the increased IRF-7 mRNA
expression, demonstrate that type I IFN signaling is activated
in psoriatic lesional skin, when compared with both healthy
skin and nonlesional skin from psoriasis patients.
IFN-a does not induce the expression of psoriasis
markers in HaCaT keratinocytes The psoriatic skin
phenotype is characterized by upregulation of several
molecules that are related to skin inflammation, and to
abnormal keratinocyte proliferation and terminal differentia-
tion (e.g., HLA-DR, ICAM-1, keratin 16, keratin 17 (K17) and
keratinocyte transglutaminase). Previously, it was shown
that in the human keratinocyte cell line HaCaT the
expression of several of these so-called psoriasis markers
could be induced by IFN-g (Bonnekoh et al, 1995; Sebok
et al, 1998; Wei et al, 1999) or interleukin-1 (Sebok et al, 1994).
To determine whether the activated IFN-a/b signaling
that is observed in psoriatic skin (Table II, Fig 2) is
Table I. Antibodies used in this study
Antibody Supplier Applicationa Dilution
rabbit a-STAT1 Santa Cruz Biotech IHC 1/1000
rabbit a-IRF-7 Santa Cruz Biotech IHC 1/50
rabbit a-IRF-9 (ISGF-3g) Santa Cruz Biotech IHC 1/50
mouse a-ICAM-1 Roche Diagnostics IHC 1/50
mouse a-ICAM-1-PE BD Biosciences Flow 1/4
mouse a-K17 DAKO IHC 1/100
Flow 1/100
mouse a-MHC-II DAKO IHC 1/400
mouse a-HLA-DR-PE BD Biosciences Flow 1/20
aIHC¼ Immunohistochemistry; Flow¼ flowcytometric analysis.
Table II. Nuclear STAT1 and IRF-9 expression is signiﬁcantly increased in psoriatic skin
% nuclei positive for
STAT1a IRF-9a IRF-7a
Healthy skin (n¼ 8) 36  3 18  5 60  6
Nonlesional psoriatic skin (n¼ 8) 40  3 42  5 63  5
Lesional psoriatic skin (n¼ 8) 56  5 56  4 61  3
aSkin sections were stained with either STAT1, IRF-9 or IRF-7 specific antibodies. Epidermal STAT1, IRF-9 and IRF-7 positive nuclei were counted and
calculated as percentage of the total number of nuclei present in the epidermis as determined by haematoxylin staining. Values are expressed as mean
%  SEM. Asterisks indicate that percentages are statistically significant higher in psoriatic skin when compared to healthy skin using the non-
parametric Mann-Whitney test (p d0.01).
Figure2
IRF-7 mRNA expression is significantly increased in epidermal
cells from psoriasis plaques. IRF-9 and IRF-7 mRNA levels were
assayed in total RNA extracts from healthy (NN, n¼6 donors),
nonlesional (PN, n¼ 6 patients), and lesional psoriatic (PP, n¼9
patients) epidermal cells. IRF mRNA levels were calculated relative to
amounts found in a standard sample, and standardized for GAPDH.
Each symbol in the left and right panel represents the relative amount of
IRF-9 mRNA or IRF-7 mRNA, respectively, for an individual patient. The
median expression levels are indicated with horizontal lines. Statistical
analysis was performed using the nonparametric Mann–Whitney test.
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functionally involved in the early initiation of the psoriasis
skin phenotype, we tested the effects of triggering this
pathway on the expression of HLA-DR, ICAM-1, and K17.
We demonstrated that components of the type I IFN
signaling pathway are present and functional in HaCaT
keratinocytes, as an increase in IRF-7 mRNA expression
was observed after stimulation of HaCaT cells with IFN-a
(Fig 3). Flow cytometric analysis, however, demonstrated
that the expression of the psoriasis markers HLA-DR,
ICAM-1, and K17 was not induced by IFN-a (Fig 4). When,
as a control, HaCaT cells were treated with IFN-g, the
expression of the above-mentioned markers was increased,
similarly as described previously (Fig 4).
To assess whether IFN-a was able to induce the
psoriasis markers with delayed kinetics, HaCaT cells were
cultured with IFN-a for 48 and 72 h. No induction of HLA-
DR, ICAM-1, and K17 expression, however, was observed
after these periods of time (data not shown).
It was demonstrated previously that IRF-9 expression is
induced by IFN-g (Levy et al, 1990; Veals et al, 1992),
resulting in a considerably higher IFN-a response (Levy et al,
1990). To evaluate the effects of this IFN-g priming on the
induction of psoriasis markers by IFN-a, HaCaT cells were
pretreated with low doses of IFN-g for 6 h. Quantitative RT–
PCR analysis indicated that these low IFN-g doses induced
both IRF-9 and IRF-7 mRNA expression. No synergistic
effects of IFN-g pretreatment on the IFN-a induced IRF-7
mRNA expression were observed (Fig 5a). The expression
of ICAM-1 was induced to some extend by the low IFN-g
doses (Fig 5b, graph b). This IFN-g pretreatment, however,
did not have any priming effect on the IFN-a response, i.e.,
ICAM-1 expression was not further induced by IFN-a after
IFN-g pretreatment (Fig 5b, graph c). Identical results were
observed for the other markers tested (e.g., HLA-DR and
K17, data not shown). Thus, combinatorial treatment of
keratinocytes with both IFN-a and IFN-g did not result in a
synergistic induction of the expression of psoriasis markers.
Stimulation of cultured healthy skin biopsies with IFN-a
increases IRF-7 mRNA expression, but does not induce
a psoriasis skin phenotype In addition to stimulation
experiments using cultured HaCaT keratinocytes, we
determined the effect of triggering type I IFN signaling in
ex vivo cultured skin biopsies. Healthy skin biopsies were
cultured for 24 h with IFN-a using a previously described
skin biopsy culturing system (Companjen et al, 2001). To
test whether in this model system IFN-a is capable of
activating the type I IFN signaling pathway, we determined
IRF-7 expression in RNA preparations from the epidermis of
the cultured biopsies. In skin biopsies from most donors,
IFN-a significantly induced epidermal IRF-7 mRNA expres-
sion (Fig 6). There was a considerable interdonor variability
in the magnitude of the induction of IRF-7 expression after
IFN-a stimulation (Fig 7, NN).
Figure 3
IFN-a induces IRF-7 mRNA expression in human keratinocytes.
HaCaT cells were cultured for 24 h with the concentrations of IFN-a
indicated. Total RNA preparations were assayed for IRF-7 expression
by RT–PCR, calculated relative to amounts found in a standard sample,
and standardized for GAPDH mRNA levels. A representative experi-
ment is shown.
Figure4
IFN-a does not induce the expression of psoriasis markers in
HaCaT cells. HaCaT cells were stimulated for 24 h with 500 U per mL
IFN-a or 500 U per mL IFN-g. Cells were analyzed for expression of
HLA-DR, ICAM-1, and K17 using flow cytometry. A comparison
between cells cultured in medium alone (dark gray line, a), medium
supplemented with IFN-a (light gray line, b), or medium supplemented
with IFN-g (black line, c) is shown in a representative experiment.
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To assess the effect of stimulation of the ISGF3/IRF-7
pathway on the expression of markers that are character-
istic for the psoriasis phenotype, immunohistochemical
analysis was performed on the cultured skin biopsies. The
expression of the markers tested (i.e., MHC-II, ICAM-1, and
K17) was increased upon culturing the skin biopsies in
medium alone when compared with fresh, not cultured skin
biopsies (Table III). Addition of IFN-a to the culture medium
did not result in an additional increase in the expression of
these markers. In contrast, addition of IFN-g did result in a
clear and significant increase in ICAM-1 expression. For the
other markers MHC-II and K17, no induction was observed
by IFN-g. This is not in agreement with previous findings
that demonstrate a significant increase in HLA-DR and K17
expression upon IFN-g stimulation of healthy skin biopsies
(Wei et al, 1999). In this study, the basal expression of MHC-
II and K17 in skin biopsies cultured in medium alone is
higher when compared with previously reported data (Table
III; Wei et al, 1999), and this expression could not be
upregulated any further by type I or type II IFN.
To exclude that induction of psoriasis markers by IFN-a
appears with delayed kinetics, skin biopsies were stimu-
lated for 48 h or 72 h with IFN-a or IFN-g. Results from
immunohistochemical analysis of these biopsies were
identical to the results presented in Table III (data not
shown).
Our data therefore demonstrate that activation of type I
IFN signaling, as accomplished by triggering healthy skin
biopsies with recombinant IFN-a, is not sufficient to induce
the initiation of the psoriasis skin phenotype in healthy skin
biopsies.
Non-lesional and lesional skin biopsies do not show an
altered sensitivity to IFN-a stimulation To assess
whether the activated ISGF3/IRF-7 signaling in lesional
epidermal cells (Table II, Fig 2) is due to an altered sensitivity
to IFN-a stimulation, nonlesional and lesional psoriatic skin
biopsies were stimulated for 24 h with 500 U per mL IFN-a.
Similarly to the healthy skin biopsies, a considerable
interpatient variability in the induction of IRF-7 expression
was observed (Fig 7). On average, IFN-a stimulation
Figure 5
In HaCaTcells, pretreatment with low doses of IFN-c does not have a priming effect on the induction of psoriasis markers by IFN-a. HaCaT
cells were treated for 6 h with the indicated concentrations of IFN-g, prior to stimulation with 500 U per mL IFN-a for 24 h. (a) IRF-9 and IRF-7 mRNA
expression were determined in total RNA preparations by RT–PCR. (b) Flow cytometric analysis of ICAM-1 expression on cells cultured in medium
alone (filled graph, a), medium with 1, 10, or 50 U per mL IFN-g without (black line, b) or with additional IFN-a stimulation (light gray line, c). For
comparison, ICAM-1 expression on cells treated with 500 U per mL IFN-g (dark gray line, d) is depicted. Results from a representative experiment of
three are shown.
Figure 6
IRF-7 mRNA expression is increased in the epidermis of healthy
skin biopsies stimulated with IFN-a. Healthy skin biopsies were
cultured ex vivo for 24 h with the concentrations of IFN-a indicated.
Dermis and epidermis were separated, and IRF-7 mRNA expression
was determined by RT–PCR in total RNA isolated from the epidermis.
Bars represent IRF-7 expression, calculated relative to amounts found
in a standard sample, and standardized for GAPDH mRNA levels.
Representative results obtained with material from one donor of eight
are shown.
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resulted in an induction of IRF-7 expression of 2.6-fold in
nonlesional, and 2.4-fold in lesional skin biopsies (Table IV).
These values were comparable with the IFN-a induced
IRF-7 expression in healthy skin biopsies (Fig 7, Table IV).
In addition, healthy and nonlesional psoriatic skin biopsies
were cultured with lower doses of IFN-a (10 and 100 U per
mL). Also when these suboptimal IFN-a concentrations
were used, the induction of IRF-7 mRNA expression was
very similar for both skin types (Table IV).
Finally, the effect of IFN stimulation on the expression of
the psoriasis markers in nonlesional psoriasis skin biopsies
was assessed by immunohistochemistry. Similarly, as
observed for healthy skin biopsies, protein expression of
MHC-II, ICAM-1, and K17 was not induced in nonlesional
biopsies stimulated with 500 U per mL IFN-a (Table III).
In summary, normal and psoriasis skin show identical
responses to type I IFN with respect to induction of IRF-7
mRNA expression and protein expression of psoriasis markers.
Discussion
In this study we demonstrate that the type I IFN signal
transduction pathway is activated in psoriatic lesional
epidermis. Activation of this signaling route in cultured
keratinocytes or skin biopsies can be mimicked by
recombinant IFN-a. Triggering of this pathway, however, is
not sufficient to induce markers that are used to define the
psoriasis skin phenotype. Furthermore, we demonstrate
that the sensitivity to type I IFN stimulation is not altered in
psoriatic nonlesional and lesional skin.
Previously published work of Hida et al (2000) suggests
that continuous, excessive IFN-a/b signaling, due to genetic
deletion of IRF-2, is the primary cause of the development
of inflammatory psoriasis-like skin lesions in mice. We here
demonstrate that also in human psoriasis the IFN-a/b
signaling pathway is activated. Dissimilar to the IRF-2–/–
mice, this is accomplished by increased expression levels
and expression patterns of the type I IFN signaling
components STAT1, IRF-9, and IRF-7, rather than by
decreased IRF-2 expression (this study; Van Der Fits et al,
2003).
Our results show that nuclear localization of STAT1 and
IRF-9 is increased in keratinocytes from psoriasis lesional
Figure 7
IFN-a stimulation of healthy, nonlesional, and lesional psoriasis
skin biopsies results in comparable induction of IRF-7 mRNA
expression. Biopsies from healthy donors (NN, n¼ 9), nonlesional (PN,
n¼8), and lesional skin (PP, n¼ 6) from psoriasis patients were cultured
for 24 h in medium alone, or medium supplemented with 500 U per mL
IFN-a. Dermis and epidermis were separated, and total RNA was
extracted from the epidermis. IRF-7 mRNA expression was assayed by
quantitative RT–PCR, and standardized for GAPDH expression. For
each individual donor or patient, the IRF-7 expression in the skin biopsy
cultured in medium with IFN-a was calculated relative to the expression
measured in the biopsy cultured in medium without additions. Each
symbol represents the relative induction of IRF-7 expression for an
individual donor/patient. The median induction levels are indicated with
horizontal lines.
Table III. IFN-a does not induce the psoriatic epidermal phenotype in normal and psoriasis nonlesional skin biopsies
MHC-IIa Keratin-17a ICAM-1a
Normal skin (n¼ 5)
Not cultured 0.8  0.1 0.2  0.2 0.2  0.1
Medium 1.5  0.2 1.8  0.5 0.4  0.2
IFN-a 1.3  0.2 1.5  0.4 0.3  0.1
IFN-g 1.6  0.3 1.1  0.1 1.8  0.4
Nonlesional psoriasis skin (n¼ 7)
Not cultured 0.8  0.2 0.0  0.0 0.1  0.1
Medium 1.3  0.2 1.3  0.3 0.4  0.1
IFN-a 1.5  0.2 1.6  0.4 0.4  0.1
IFN-g 1.8  0.3 1.8  0.4 3.3  0.2
aNormal or non-lesional psoriasis skin biopsies were not cultured, or cultured for 24 h in medium, or in medium supplemented with 500 U/ml IFN-a or
500 U/ml IFN-g. Cryosections were stained for the markers indicated and semi-quantitatively scored. Values indicate the mean score  SEM. Asterisks
indicate statistically significant differences in marker expression between the biopsy cultured in the medium with IFN, when compared to be biopsy
cultured in medium alone (po0.05) tested using the parametric T-test.
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skin, implying functional activation of the ISGF3 complex.
This was confirmed by high levels of IRF-7 mRNA, a gene
that is transcriptionally activated by nuclear ISGF3. Also in
nonlesional skin, nuclear localization of IRF-9 is significantly
increased (Table II). In this skin type, however, functional
activation of the ISGF3 complex is not detectable, as IRF-7
mRNA expression remains unaltered (Fig 2). This discre-
pancy might be due to methodologic differences between
the assays used. To assay the IRF-9 nuclear translocation,
we counted the number of epidermal cells that express
nuclear IRF-9 using immunohistochemistry, thereby making
a clear distinction between cells that do or do not display
nuclear IRF-9 localization. In contrast, IRF-7 mRNA expres-
sion represented the average expression level in the
complete population of epidermal cells, irrespective of the
nuclear IRF-9 expression. Thus the increase in IRF-9
nuclear translocation that is observed in nonlesional
psoriatic skin might not be sufficient to cause measurable
increases in IRF-7 mRNA expression in the total population
of epidermal cells.
In this study we used a generally accepted definition of
the psoriasis skin phenotype based on the epidermal
expression of markers that are associated with skin
inflammation (i.e., HLA-DR and ICAM-1) and altered
differentiation and proliferation of keratinocytes (i.e., K17).
These markers are upregulated in psoriatic keratinocytes,
and widely used to monitor improvement of psoriasis upon
therapy (e.g., de Jong et al, 1991; Rizova et al, 1994;
Trepicchio et al, 1999). Here we show that expression of
these markers on HaCaT keratinocytes is not induced by
triggering the IFN-a/b signal transduction pathway. As the
human skin is a complex tissue comprising many different
cell types, results obtained in HaCaT keratinocytes might
not be representative for the in vivo situation in skin.
Experiments that were performed using skin organ cultures
yielded identical results, i.e., no induction of psoriasis
markers by IFN-a. Together this suggests that type I IFN
does not have a direct effect on keratinocytes in the
initiation phase of psoriasis. In contrast, a direct role for IFN-
g in the initiation of inflammatory skin diseases has been
demonstrated by in vivo studies in transgenic mice (Carroll
et al, 1997). These data are supported by results from in
vitro experiments showing that the expression of psoriasis
markers can be induced in HaCaT cells and skin biopsies
cultured with IFN-g (this study, Bonnekoh et al, 1995; Sebok
et al, 1998; Wei et al, 1999).
Type I IFN can have several immunomodulatory effects
(reviewed by Tompkins, 1999). For example, IFN-a provides
an important signal for the differentiation of CD4þ T cells
into T helper 1 cells. Furthermore, IFN-a is responsible for
the amplification of the CD8þ T cell responses and natural
killer cell activation. Both CD4þ T helper 1, CD8þ T cells
and natural killer cells have been implicated to be important
in the pathogenesis of psoriasis (Nickoloff, 1999). Thus, the
effects of type I IFN during the initiation phase of psoriasis
might involve effects exerted on T or natural killer cells,
rather than directly on keratinocytes. This might explain the
failure of IFN-a to induce the psoriatic epidermal phenotype
in cultured skin biopsies, which are almost devoid of T cells.
Numerous previous studies demonstrated that psoriasis
lesional skin displays an altered sensitivity to IFN-g. For
example, it was shown that IFN-g-induced expression of
IRF-1, a transcription factor that occupies a central role in
IFN-g signaling (Taniguchi et al, 2001), was decreased in
cultured psoriatic keratinocytes (Jackson et al, 1999; Chen
et al, 2000). We observed similar results on the expression
of IRF-1 when stimulating psoriasis lesional skin biopsies
with recombinant IFN-g (data not shown), validating the
experimental set-up used in this study. Here we demon-
strate that the induction of IRF-7 expression by type I IFN is
similar in healthy, nonlesional, and lesional psoriatic skin.
Thus the observed increase in ISGF3/IRF-7 signaling in
lesional psoriasis skin (Table II, Fig 2) is not caused by an
increased sensitivity of psoriatic skin to type I IFN. In
addition, also with respect to the induction of psoriasis
markers, the sensitivity to type I IFN signaling in healthy and
nonlesional psoriasis skin biopsies was identical. In both
types of skin biopsies, IFN-a was not able to induce the
initiation of the psoriasis skin phenotype.
Demonstration of the activated type I IFN signaling
pathway in psoriatic skin in this study is in complete
agreement with increased expression levels of various IFN-
inducible proteins such as MxA and 20-50 oligoadenylated
synthetase that have been described previously (Schmid
et al, 1994; Fah et al, 1995). These alterations might be
caused by an enhanced type I IFN production in psoriatic
skin. Reports on this topic are conflicting. Immunohisto-
chemical analysis showed that IFN-a protein was not
detectable in healthy skin, or in stable psoriatic skin (Livden
et al, 1989). In contrast, Schmid et al (1994) demonstrated
that IFN-a mRNA was expressed throughout the epidermis
of stable psoriatic skin lesions, whereas no specific signals
Table IV. IRF-7 mRNA expression is induced by IFN-a to similar levels in healthy, nonlesional and lesional skin biopsies
Concentration IFN-a Fold induction in IRF-7 expressiona
NN (n¼ 9) PN (n¼ 6 or 8) PP (n¼ 6)
10 U/ml 1.4  0.4 1.1  0.2 NDb
100 U/ml 2.2  0.6 1.9  0.3 NDb
500 U/ml 4.0  1.3 2.6  0.4 2.4  0.7
aBiopsies from healthy donors (NN), nonlesional skin (PN) and lesional skin (PP) from psoriasis patients were cultured for 24 h with the concentrations
of IFN-a indicated. The relative induction in IRF-7 mRNA expression was assayed and calculated as described in the legend of Figure 6. Values represent
mean IRF-7 induction  SEM. Statistical analysis using the non-parametric Mann-Whitney test revealed no significant differences in IRF-7 induction
between NN, PN and PP.
bND: not determined.
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were revealed in nonlesional skin from psoriasis patients or
in skin from healthy donors. Recently, it was demonstrated
that the number of plasmacytoid dendritic cells, cells that
are capable of producing high levels of IFN-a, is significantly
increased in psoriatic skin (Wollenberg et al, 2002). Thus,
the observed ISGF3/IRF-7 signaling in psoriasis skin lesions
might well be caused by IFN-a production by infiltrating
plasmacytoid dendritic cells.
Recently, a novel type I IFN was described, IFN-k, which
is expressed in human keratinocytes (LaFleur et al, 2001).
Whereas healthy skin only showed scattered IFN-k-positive
cells in the dermis, numerous monocytes and dendritic cells
expressing IFN-k were present in the epidermis and dermis
of chronic skin lesions from psoriasis patients. Furthermore,
keratinocytes in basal and suprabasal epidermal cell layers
showed IFN-k expression (Nardelli et al, 2002). As IFN-k,
like IFN-a, signals through the type I IFN receptor (LaFleur
et al, 2001), it is possible that the increased ISGF3/IRF-7
signaling observed in this study is directly linked to
enhanced IFN-k expression. Elucidation of the functional
role for IFN-k in the skin immune system would shed more
light on the contribution of type I IFN to the pathogenesis of
psoriasis.
In summary, we demonstrate that the expression of type
I IFN signaling components is markedly increased in
psoriasis skin lesions. Triggering this pathway through its
physiologic receptor, however, does not result in the
induction of the regenerative epidermal phenotype of
psoriatic lesions. Furthermore, responses to IFN-a stimula-
tion do not differ between healthy, nonlesional, and lesional
psoriatic skin. Our data might suggest that activated type I
IFN signaling is dispensable during the initiation phase of
psoriasis, although a functional role in the maintenance of
the skin inflammation cannot be excluded. Alternatively,
activation of the type I IFN system might play an indirect role
in the induction of the psoriasis skin phenotype, possibly by
exerting its effects on other cell types, such as IFN-g
secreting natural killer or T cells, rather than directly on
keratinocytes.
Materials and methods
Patient material All human tissue samples were obtained after
informed consent and approval of the medical ethics committee of
the Erasmus MC, the Netherlands. Normal skin samples were
obtained from 23 females (aged 17–59 y, median age 36 y),
undergoing breast or abdominal plastic surgery (Sint Franciscus
Hospital Rotterdam, Erasmus MC, the Netherlands). Lesional and
nonlesional skin samples were taken from 29 patients (11 females,
18 males, aged 19–73 y, median age 48 y) with stable plaque-type
psoriasis (Ziekenhuis Walcheren Vlissingen, the Netherlands). Prior
to participation in this study, psoriasis patients received no topical
treatment for a period of at least 3 wk, and no systemic treatment
for at least 2 mo.
Isolation of epidermal cell suspensions Split skin specimens
were obtained using a portable dermatome (Padgett Instruments
Inc., Kansas City, Missouri). Epidermal cell suspensions were
prepared using standard methods (Prens et al, 1991; Van Der Fits
et al, 2003). Viability of the cells was checked by trypan blue
exclusion.
Culturing of skin biopsies and HaCaT cells Biopsies were taken
from skin of healthy individuals or psoriasis patients using a 3 mm
diameter biopsy punch (Stiefel, Leuven, Belgium). Biopsies were
cultured as described previously (Companjen et al, 2001). Briefly,
four 2 mm holes (two holes in case of culturing psoriasis skin
biopsies) were punched in a Netwell filter (pore size: 0.75 mm;
Corning Costar, Corning, New York). In each hole, one biopsy was
inserted. The filter was placed in a 12-well culture plate containing
1 mL IMDM medium (GibcoBRL, Paisley, UK) supplemented with
1% human serum (Sigma, St Louis, Missouri), 100 U penicillin per
mL, 100 mg streptomycin per mL, and 2 mM ultra glutamine
(BioWhittaker, Walkersville, Maryland). Biopsies were stimulated
with clinically approved IFN-a (IntronA IFN-a2b, Schering-Plough,
Kenilworth, New Jersey) or IFN-g (Boehringer Ingelheim, Heidel-
berg, Germany) for 24 h at 371C and 5% CO2. After culturing, one
of the biopsies was immersed in TissueTek (Bayer, Munich,
Germany), snap frozen in liquid nitrogen and stored at 801C until
use. The remaining biopsies were incubated in phosphate-buffered
saline (PBS) containing 5 mg thermolysin per mL (Protease type X,
Sigma) for 2 h at 371C. The epidermis was separated from the
dermis using fine forceps. Epidermal cells were lyzed in 250 mL
lysis buffer (GenElute Mammalian Total RNA kit, Sigma) and stored
at 801C until use.
HaCaT cells (Boukamp et al, 1988) were cultured in RPMI 1640
medium (GibcoBRL) supplemented with 5% heat inactivated fetal
calf serum (BioWhittaker), 100 U penicillin per mL, 100 mg
streptomycin per mL, and 2 mM ultra glutamine at 371C and 5%
CO2. The cells were passaged every 7 d.
Immunohistochemistry Six micrometer cryosections of snap
frozen biopsies were cut using a cryostat (Jung Frigocut 2800 E,
Leica, Rijswijk, the Netherlands) and stored until use at 801C in a
sealed box containing silica gel. Sections were fixed in acetone
(Fluka Chemie AG, Buchs, Switzerland) containing 0.5% H2O2 for
10 min at room temperature. Sections for immunohistochemical
staining for STAT1, IRF-7, and IRF-9 were fixed by dipping in
acetone, air-drying, incubating in Zamboni’s fixative (2% w/v
paraformaldehyde, 15% v/v saturated picric acid, 1.88% w/v
NaH2PO4.H2O, pH 7.3) for 30 min, dipping in 80% ethanol and
rinsing for 30 min in PBS in the presence of 0.5% H2O2 during the
last 10 min. After fixation, sections were preincubated for 10 min in
PBS at room temperature. Endogenous peroxidase activity was
revealed with 4-chloro-1-naphthol (Sigma), resulting in a dark blue
precipitate. Slides were washed with PBS containing 0.05% Tween
20 (Merck, Whitehouse Station, New Jersey) and incubated with
primary antibody (Table I) overnight at 41C, or for 1 h at room
temperature. This was followed by incubation for 30 min with
biotin-linked secondary rabbit-anti-mouse or donkey-anti-rabbit
antibody and peroxidase-linked avidin (DAKO, Glostrup, Denmark).
Biotinylated major histocompatibility complex (MHC) II (HLA-DP-
DQ-DR) antibody was detected directly by streptavidin-linked
peroxidase. 3-amino-9-ethylcarbazole (Sigma) was used as the
chromogen, resulting in a bright red staining. Sections incubated
with an antibody of the same isotype as the specific antibody but
of irrelevant specificity served as controls. MHC-II, ICAM-1, and
K17 expression on keratinocytes was evaluated independently by
two observers using semiquantitative grading from 0 to 4, as
described previously (Griffiths et al, 1991); 0¼ negative; 1¼weak
staining, 2¼moderate staining; 3¼ strong staining; 4¼ very strong
staining. STAT1, IRF-7, and IRF-9 expression was quantified
independently by two observers by counting positive nuclei in
the epidermis. The total number of nuclei present in the epidermis
of the different biopsies was counted in slides stained with
hematoxylin.
Real-time quantitative reverse transcription–polymerase chain
reaction (RT–PCR) Total RNA was extracted from epidermal cell
suspensions, HaCaT (1–2  106 cells) or epidermal sheets using
RNAzolB (Campro Scientific, Veenendaal, the Netherlands) or the
GenElute Mammalian Total RNA kit (Sigma). Using 1 mg of the total
RNA as template, copy DNA (cDNA) was obtained using the AMV
Reverse Transcription System (Promega, Madison, Wisconsin).
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Real-time quantitative RT–PCR was performed as described
previously (Van Der Fits et al, 2003). Primer sequences (forward
primer and reverse primer, respectively) and their optimal con-
centrations were: IRF-7 (TCC CCA CGC TAT ACC ATC TAC CT (50
nM), ACA GCC AGG GTT CCA GCT T (50 nM)) and IRF-9 (GGA
GCA GTC CAT TCA GAC ATT G (50 nM), ATG AAG GTG AGC AGC
AGT GAG TAG T (900 nM)). The FAM-labeled probes (PE-Applied
Biosystems, Foster City, California) CTT CGG GCA GGA CCT GTC
AGC TG (IRF-7) and TCA GAG GTC CCT GGA GTT TCT GCT TCC
T (IRF-9) were used at a concentration of 100 nM. GAPDH mRNA
levels were measured as a control to normalize for RNA input. For
this, a commercially available primer/probe mixture was used (PE-
Applied Biosystems). There was no consistent effect of IFN
treatment on the GAPDH mRNA expression, validating the use of
this gene as control gene. IRF mRNA levels were calculated
relative to amounts found in a standard sample, and corrected for
GAPDH mRNA levels.
Flow cytometric analysis HaCaT cells were seeded into six-well
culture plates (Nalgene Nunc International, Rochester, New York) at
a density of 3.5  105 cells per well in 2 mL. The cells were allowed
to adhere and to grow for 24 h. Cells were rinsed with PBS and
stimulated for 24 h in fresh medium with or without IFN-a or IFN-g.
Cells were detached with PBS containing 0.025% trypsin and
0.1% EDTA, washed in PBS and resuspended at a concentration of
10  106 cells per mL. Forty microliters of cell suspension was
mixed with 40 mL of the primary antibody solution (Table I) and
incubated for 10 min at room temperature. Prior to labeling with
monoclonal antibodies against K17, cells were permeabilized using
Intraprep (Immunotech, Marseille, France). Cells were washed
twice with PBS/0.2% bovine serum albumin (pH 7.8), and, if the
primary antibody was not directly labeled, incubated with a
secondary antibody, goat-anti-mouse-PE (Sanbio, Uden, the
Netherlands) for 10 min room temperature. Cells were washed
twice, resuspended in FACS buffer and analyzed on a flow
cytometer (FACScan, BD Biosciences, Franklin Lakes, New York).
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